Literature DB >> 34485451

First study of hepatitis delta virus in Algeria: Seroprevalence and risk factors in Setif region (east of Algeria).

Abdelkader Gasmi1, Wahiba Guenifi1, Amel Ouyahia1, Mounira Rais1, Houda Boukhrissa1, Abderahmen Hachani1, Salah Mechakra1, Slimen Laouamri2, Abderezak Touabti3, Abdelmadjid Lacheheb1.   

Abstract

BACKGROUND: No recent data are available on hepatitis delta virus (HDV) prevalence in Algeria. For this reason we conducted an epidemiological study, cross-sectional seroprevalence of HDV in the region of Setif.
METHODS: Between 2011 and 2014, sera samples of 500 patients (carrying HBsAg) admitted to the Division of Infectious Diseases Teaching Hospital, Setif (east of Algeria), were tested for anti-HDV-IgG ab (ETI-AB-DeltaK-2).
RESULTS: The prevalence of HDV obtained is estimated at 2.4%. The prevalence ranges from 1% in chronic hepatitis to 11.1% in cirrhotic hepatitis (low endemic area). Seropositivity rate is closely correlated with age (Odds ratio [OR] = 9.98, p = 0.000) and gender (OR = 0.24, p = 0.025); it reaches 58.3% in the age group of 51-60 years and 0% in children (age group 1-15 years); it represents 75% in females and 25% in males. The presence of familial cases of HBsAg positive (OR = 4.54, p = 0.006), the endoscopic procedure (OR = 6.54, p = 0.000) and tattooing (OR = 20, p = 0.000) were found to be the transmission risk factors. A statistically significant relationship was found between the positivity of anti-HDV and advanced liver disease, cirrhosis (OR = 9. 16, p = 0.000). A significant correlation was found between the positivity of anti-HDV with diabetes (OR = 6.83, p = 0.000), obesity (OR = 4.19, p = 0.009) and viral suppression B (OR = 5.69, p = 0.003).
CONCLUSION: Our results show that HDV infection is low in Algeria. Research for total anti-HDV should be part of the initial assessment of patient care with viral hepatitis B as well as the prevalence of other viruses (hepatitis C [HCV] and HIV). A multicentre study should be carried out to know the importance of HDV infection and identify the risk groups.
© 2019. The Authors.

Entities:  

Keywords:  Algeria; Hepatitis Delta Virus; Setif; prevalence; risk factors

Year:  2019        PMID: 34485451      PMCID: PMC8378082          DOI: 10.4102/sajid.v34i1.110

Source DB:  PubMed          Journal:  S Afr J Infect Dis        ISSN: 2312-0053


Introduction

First described in 1977 by Rizzetto et al.,[1] the hepatitis delta virus (HDV) is a small virus 1.7 kb RNA, single-stranded, negative polarity considered a human agent. Biological characteristics not fully completing the virus definition criteria and its dependence on a helper virus[2] has placed it under the satellite virus group.[3] In 1993, the International Committee on Taxonomy of Viruses proposed to classify it in a member of the free-floating genus Deltavirus[4] of which it is the sole representative.[5] One of its characteristics is its high genetic variability with eight separate genotypes HDV (HDV1–8).[6,7] Hepatitis delta is an ubiquitous transmissible infection, reported in every country in which it was sought.[8,9] Nevertheless, there is a varying prevalence from one country to another country and from one region to another region within the same country. Early studies in the eighties have found a mean prevalence estimated at 5% in the carrier population of HBsAg. Hepatitis delta infection remains a major public health problem, and it is currently estimated that, worldwide, between 15 and 20 million people are positive for the viral hepatitis delta (VHD) and it affects all ages, but its distribution is not uniform.[10,11] The epidemiology of HDV has changed; in fact, factors such as vaccination and public health measures against acquired immunodeficiency syndrome (AIDS) combined with improvements in hygienic conditions have contributed to control the hepatitis B virus infection and, as a direct consequence, the decrease in the prevalence of infection with HDV.[12,13] Algeria is exposed to the risk of reintroduction by migrants, that is, neighbours, coming mainly from its southern countries: 29% in Niger,[14] 19.7% in Mauritania[15] and 13.9% in Mali.[16] Furthermore, we noted the presence of new genotypes such as the VHD5 genotype that represents 10.7% of isolated strains in Mauritania.[7] In Algeria, the epidemiology of this hepatitis is still very little known. Only four studies were conducted on limited numbers and populations. For this reason, we conducted a cross-sectional seroprevalence study of HDV in the Setif region (Figure 1).[17]
FIGURE 1

Location of Setif city.[17]

Location of Setif city.[17]

Materials and methods

Between 2011 and 2014, sera samples of 500 patients (carrying HBsAg) admitted to the Division of Infectious Diseases Teaching Hospital, Setif (east of Algeria), were tested for anti-HDV-IgG ab (ETI-AB-DeltaK-2). The patients are from five cities in the east of Algeria (Setif, Bourdj-Bou-Arrerdj, Msila, Mila and Bejaia). Inclusion criteria: All HBsAg patients in this study at the Division of Infectious Diseases Teaching Hospital, Setif. Exclusion criteria: Patients refusing to participate. A questionnaire was completed for each patient including information about age, sex, marital status, number of wives and children, socio-economic level, risk exposure during life, discovery circumstances, comorbidity and specific situations such as, overweight and obesity, diabetes, pregnancy, history of hemodialysis and co-infection with HCV and co-infection with HIV. Results in clinical and biochemical examinations data were correlated with those of the HBV viral load. According to the stage of their liver disease, patients were divided into four groups: first group, acute hepatitis B; second group, chronic hepatitis B; third group, cirrhosis; and fourth group, hepatocellular carcinoma.

Statistical analysis

Data analysis was performed using SPSS version 21.0 (SPSS Inc., USA). We used the technique of descriptive statistics with the estimated prevalence with a confidence interval (CI) ww 95%; chi-square test and Fishers exact test were used for the comparison of distributions and calculation of measures of epidemiological associations (odds ratio [OR]) with 95% CI. A p-value < 0.05 was considered significant.

Ethical consideration

The study was approved by the research ethical committee of University Ferhat Abbes Setif, Algeria. All participants gave their consent before data and blood samples were collected.

Results

The study of 500 sera samples from patients with HBsAg in different stages of the disease shows 12 patients having anti-delta positive total IgG, a prevalence equal to 2.4% with a 95% CI [1.1% – 3.7%]. The prevalence of HDV is higher among women (75% of positive anti-HDV). The difference was statistically significant (OR = 0.24, p = 0.025) (Table 1).
TABLE 1

Relationship with demographic characteristics, diabetes, pregnancy, history of hemodialysis, co-infection with HCV or HIV, biological and virological parameters and hepatitis delta virus.

VariableIgG-anti-delta positivity
IgG-anti-delta negativity
P OROR: Min-Max
Positive%Negative%
Age
Mean of age55.5 ± 12.5-38.5 ± 15.5-0.000--
Age group (51–60)758.31083.30.00010.03–32.5
Gender
Male32528157.60.0255.00.06–0.9
Female97520742.4---
Marital status
Single0013227.90.031.031.01–1.05
Married1210034171.1---
Number of children
Means ± SD4.83 ± 2.65-2.83 ± 2.31-0.004--
≥ 5758.36819.90.0015.61.7–18.2
Profession
Unemployed1083.325953.10.034.40.9–20.3
Officials18.368180.38--
Liberal officials18.38517.40.41--
Students00438.80.28--
Health workers00132.70.32--
BMI (Kg/m2)
Means ± SD
Overweight (BMI: 25.00–29.99)216.717336.60.150.30.1–1.6
Obesity (BMI ≥ 30)650.59119.20.0094.11.3–13.3
Diabetes510.6469.40.0006.92–22
Pregnancy0031150.20--
History of hemodialysis00122.60.58--
Co-infection with HCV18.3265.30.64--
Co-infection with HIV0030.60.87--
ALT (IU/L)
Means ± SD52.6 ± 19-45 ± 44.7-0.62--
> 4088015936.60.0056.97.3–160.4
Platelets (n/mm3 × 106)
Means ± SD172 ± 89-200 ± 81-0.23--
< 150 000758.335272.10.2934.37.3–160.4
HBeAg positivity133.37226.60.79--
Serum HBV DNA
< 100 IU/mL5506514.90.0035.71.6–20.2
> 4.3 log (10) copies/mL22010223.40.78--

ALT, alanine transaminase; PLT, platelets; SD, standard deviation; OR, odds ratio; Min, minimum; Max, maximum.

Relationship with demographic characteristics, diabetes, pregnancy, history of hemodialysis, co-infection with HCV or HIV, biological and virological parameters and hepatitis delta virus. ALT, alanine transaminase; PLT, platelets; SD, standard deviation; OR, odds ratio; Min, minimum; Max, maximum. The average age of patients with VHD (55.5 ± 12.5 years) is significantly higher than that of patients infected with HBV alone (38.56 ± 15.5 years), and the difference was statistically significant (p = 0.000). The city of Msila displays the highest rate of 6.9% 0% – 17.2%, followed by the city of Bourdj-Bou-Arrerdj with a rate of 2.9% 0% – 7.2% and the city of Setif with a rate of 2% 0.8% – 3.5%. In the city of Bejaia and Mila, the prevalence rate is zero (Table 2).
TABLE 2

Prevalence of HDV by city.

City N %IgG-anti-delta+
P
Positive%
Setif39478.882.00.29
Bourdj-Bou-Arrerdj6913.822.90.77
Msila295.826.90.10
Mila40.800.00.75
Bejaia40.800.00.75

Total 500 100 12 100 -
Prevalence of HDV by city. Statistical analysis revealed a significant relationship between marital status and positivity of anti-HDV (OR = 1.03, p = 0.03), but there was no relationship between the number of wives and positivity of anti-HDV. The average number of children in patients with VHD (4.83 ± 2.65) is significantly higher than that of those infected with HBV alone (2.83 ± 2.31), and the difference is statistically significant (OR = 1.03, p = 0.004). A significant relationship was found between certain risk factors and transmission (the positive family history of hepatitis B OR = 4.54, p = 0.006, endoscopy OR = 6.54, p = 0.000, tattoos OR = 20, p = 0.000) (Tables 1 and 3).
TABLE 3

Relationship with risk factors and hepatitis delta virus.

VariableIgG-anti-delta positivity
IgG-anti-delta negativity
P ORχ2 test
Positive%Negative%
Dental procedures1083.339781.40.861.10.03
Blood transfusion32512325.20.980.90.20
Surgery866.723548.20.200.91.6
Endoscopy758.38617.60.0006.512.8
Sexual358.36212.70.212.21.56
Cupping216.75310.90.521.60.40
Positive family History758.311523.60.0064.57.67
blood exposure accident00.0163.30.520.970.40
Percutaneous exposure (shaving at a barbers shop)32530061.50.0110.26.52
Tattoo history32581.60.0002029.7
Piercing18.3510.02205.27
Not identified00.0132.70.560.970.32

OR, odds ratio.

Relationship with risk factors and hepatitis delta virus. OR, odds ratio. Significant relationship between viral hepatitis delta and some of these factors investigated was found, such as number of children (OR = 5.6, p = 0.001) and obesity (OR = 4.19, p = 0.000) (Table 1). Diabetes (OR = 6.83, p = 0.000), ALT (OR = 6.9, p = 0.005) and HVB DNA (OR = 5.69, p = 0.003) were correlated with anti-HDV serology antibodies (positive or negative) (Table 1). Prevalence of HDV seropositivity varies according to the liver disease stages: acute hepatitis (3.6%) with a 95% CI 0% – 9%, chronic hepatitis (1%) with a 95% CI 0% – 2%, cirrhosis (11.1%) with a 95% CI 1.8% – 20.3% and hepatocellular carcinoma (0%) (Table 4).
TABLE 4

Prevalence of hepatitis delta virus infection among hepatitis B virus (HBV) infected subjects with liver disease.

HBV-related liver disease group n IgG-anti-delta positivity
P 95% CI0R
Positive%
Acute hepatitis5523.60.520–9-
Chronic hepatitis384410.0000–20.2
Cirrhosis54611.10.0001.8–20.39.6
Hepatocellular carcinoma700.00.67--
Total 500 12 - - - -

OR, odds ratio.

Prevalence of hepatitis delta virus infection among hepatitis B virus (HBV) infected subjects with liver disease. OR, odds ratio.

Discussion

This study demonstrates that Algeria is in a low endemic region for VHD. The available data studies on hepatitis delta are exposed in Table 5.[18,19]
TABLE 5

Prevalence of viral hepatitis delta in Algeria.

StudyAcute hepatitis
Chronic hepatitis
Cirrhosis
Hepatocellular carcinoma
Prevalence
%Positive (n)%Positive (n)%Positive (n)%Positive (n)%Positive (n)
Nouasria 198463/50------63/50
Belabbes 19863.73/8116.61/1615.15/33--7.59/120
Berkane 2003--6.813/44----6.813/44
Khelifa 2009--1.331/75----1.331/75
Our study3.62/5314/38411.16/5400/72.412/500
Prevalence of viral hepatitis delta in Algeria. Our prevalence is comparable to those found in most of the Maghreb countries (Tunisia: 6.8%,[20] Egypt: 4.7%,[21] Morocco: 1.17%,[22] and Libya: 10.8%[23]). In contrast to our results, Mauritania shows a high prevalence of 19.7%,[15] and in Central Africa, Makuwa[24] has reported a very high prevalence of 66.7% in Gabon, recalling the first outbreaks of hepatitis delta described in the 1980s in the Central African Republic.[25] In most countries of West Africa,[26] especially those sharing borders with Algeria, high rates are recorded. Our prevalence is above that reported by Dusheiko in South Africa[27] (0.6%) (Figure 2).
FIGURE 2

Prevalence of hepatitis delta in Africa.

Prevalence of hepatitis delta in Africa. Our results are lower than the higher rates reported in Italy; as in several European countries, Italy has witnessed a significant decrease in its VHD infection rates.[12,28] This study allowed us to have updated information about the infection in at least three cities. The prevalence varies from one city to another. This difference in prevalence between the three cities may be related to the incidence of viral hepatitis B (estimated in Algeria at 2.16%, and 2.68% in Msila city).[29,30] This same observation was reported by Djebbi[20] in Tunisia. The prevalence of hepatitis D (HVD) in Algeria is closely related to gender and age. In most studies, a male predominance has been noted[8,29] with the exception of some countries or some regions. More recently, the Hepatitis Delta International Network (HDIN) Register[31] which includes 12 worldwide study centres for delta hepatitis, reported results showing predominance of one gender over the other according to the patient origin. This study has provided us with some information on the exposure of risk factors in life. The presence of the family cases of viral hepatitis B is one of the found risk factors which is in agreement with that reported by Fattovich[32] in Italy (8.1%, p = 0.004). The second risk factor found was the endoscopic procedure. Few studies have focused on this mode of transmission. Our results are in agreement with those of Gheorghe in Romania[33] (36.8%, p = 0.0001). The risk of virus transmission during endoscopy is low, because the cleaning and disinfection practice insures a significant viral inactivation.[34] Thirdly, tattooing was found to be a significant risk factor in patients with VHD. During tattooing, the muco-cutaneous barrier is broken accompanied by a break of blood capillaries, leading a moderate and transient bleeding which is enough exposure to the risk of infections with hepatitis viruses or HIV. Traditional methods of tattooing and poor hygiene practices contribute mainly to the increased risk of transmission. Exposure to other risk factors is not significant. This is the only study that was interested in the association of delta hepatitis and diabetes. The diabetic population is being exposed to a multiplicity of risk factors for hepatitis; furthermore, diabetes favours the development of severe forms of liver disease (cirrhosis and hepatocellular carcinoma). Our study sheds light on the prevalence of hepatitis delta virus at different stages of liver disease. This rate is consistent with that found by Belabbes[18] who has reported a prevalence of 15.15% (5/33). Several authors have noted the frequency of anti-HDV antibodies in patients at the cirrhosis stage.[35] In conclusion, our results show that HDV infection is low in Algeria. Research for total anti-HDV should be part of the initial assessment of patient care with viral hepatitis B as well as the search of other viruses (HCV and HIV), and the completion of a multicentre study should be carried out to establish the prevalence of HDV and identify the risk groups.
  24 in total

Review 1.  Delta hepatitis: an update.

Authors:  Patrizia Farci
Journal:  J Hepatol       Date:  2003       Impact factor: 25.083

Review 2.  Origin of hepatitis delta virus.

Authors:  John Taylor; Martin Pelchat
Journal:  Future Microbiol       Date:  2010-03       Impact factor: 3.165

3.  Virological and epidemiological features of hepatitis delta infection among blood donors in Nouakchott, Mauritania.

Authors:  Wael Mansour; Mohamed-Abdellahi Bollahi; Cheikh-Tijani Hamed; Ségolène Brichler; Frédéric Le Gal; Alexandra Ducancelle; Baidy Lô; Emmanuel Gordien; Michel Rosenheim; Françoise Lunel
Journal:  J Clin Virol       Date:  2012-06-14       Impact factor: 3.168

4.  Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers.

Authors:  M Rizzetto; M G Canese; S Aricò; O Crivelli; C Trepo; F Bonino; G Verme
Journal:  Gut       Date:  1977-12       Impact factor: 23.059

5.  Hepatitis Delta Virus Infection in Romania: Prevalence and Risk Factors.

Authors:  Liana Gheorghe; Irma Eva Csiki; Speranta Iacob; Cristian Gheorghe; Anca Trifan; Mircea Grigorescu; Adriana Motoc; Andra Suceveanu; Manuela Curescu; Florin Caruntu; Ioan Sporea; Ciprian Brisc; Ion Rogoveanu; Razvan Cerban; Letitia Tugui; Andrea Alexandrescu
Journal:  J Gastrointestin Liver Dis       Date:  2015-12       Impact factor: 2.008

Review 6.  Hepatitis delta: the rediscovery.

Authors:  Mario Rizzetto; Seyed Moayed Alavian
Journal:  Clin Liver Dis       Date:  2013-07-03       Impact factor: 6.126

7.  Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep).

Authors:  G Fattovich; G Giustina; E Christensen; M Pantalena; I Zagni; G Realdi; S W Schalm
Journal:  Gut       Date:  2000-03       Impact factor: 23.059

8.  Chronic hepatitis D: a vanishing Disease? An Italian multicenter study.

Authors:  G B Gaeta; T Stroffolini; M Chiaramonte; T Ascione; G Stornaiuolo; S Lobello; E Sagnelli; M R Brunetto; M Rizzetto
Journal:  Hepatology       Date:  2000-10       Impact factor: 17.425

9.  Outcome of chronic delta hepatitis in Italy: a long-term cohort study.

Authors:  Grazia Anna Niro; Antonina Smedile; Antonio Massimo Ippolito; Alessia Ciancio; Rosanna Fontana; Antonella Olivero; Maria Rosa Valvano; Maria Lorena Abate; Domenica Gioffreda; Gian Paolo Caviglia; Mario Rizzetto; Angelo Andriulli
Journal:  J Hepatol       Date:  2010-07-29       Impact factor: 25.083

10.  [Serological markers, viral RNA and genotype of hepatitis delta virus in HBs antigen positive Tunisian patients].

Authors:  A Djebbi; W K Rebai; O Bahri; N Hogga; A Sadraoui; H Triki
Journal:  Pathol Biol (Paris)       Date:  2008-11-26
View more
  1 in total

1.  Dermatological and Ophthalmological Inflammatory, Infectious, and Tumoral Tattoo-Related Reactions: A Systematic Review.

Authors:  Juliana Muñoz-Ortiz; Mariana Teresa Gómez-López; Paula Echeverry-Hernández; Mario Federico Ramos-Santodomingo; Alejandra de-la-Torre
Journal:  Perm J       Date:  2021-05-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.